Skip to main content
Log in

Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

The time delay between drug plasma concentrations and effect has been modeled most commonly by the effect compartment approach, assuming first-order monoexponential equilibrium kinetics between plasma and effect site. So far this assumption has not been rigorously probed. The purpose of the present investigation was to model the delay between amobarbital plasma concentrations and EEG effect using a new approach based on system analysis principles. This approach models the equilibrium between plasma and effect site without assuming a specific kinetic structure. Assuming linear distribution kinetics between plasma and effect site, the relationship between the two variables may be described by a convolution type of linear operation, involving a conductance function ϕ(t),which is approximated by a sum of exponentials. Six male Wistarderived rats received an iv infusion of amobarbital at a rate of 10mg/kg per min until isoelectric periods of 5sec or longer appeared on the EEG. Frequent arterial blood samples were obtained and EEG was continuously quantified using aperiodic analysis. The amplitudes in the 2.5–30Hz frequency band were used as EEG effect measure. The delay between plasma concentrations and EEG effect was best modeled by a biexponential conductance function. The use of a biexponential conductance function resulted in a significant further reduction (41 ± 10%)in hysteresis when compared to a monoexponential function, indicating that the assumption of simple first-order monoexponential equilibration kinetics is inadequate. The use of a biexponential conductance function also resulted in a significantly different shape of the effect site concenration- EEG effect relationship and hence the estimated pharmacodynamic parameters, when compared with a monoexponential function. This relationship showed a biphasic behavior, with EEG effects being maximal at amobarbital concentrations of 29.6± 1.3mg/L. At 80.2±2.0mg/L the EEG effect was reduced 50%below baseline values. A comparison was made with the equilibration between amobarbital plasma and cerebrospinal fluid (CSF) concentrations. Six male Wistarderived rats received an iv infusion of amobarbital, 10mg per min for 15min. Arterial blood and CSF samples were taken simultaneously at regular intervals. The equilibration between plasma and CSF concentrations was best fitted by a monoexponential conductance function. Significant differences in equilibration profiles of CSF and effect site with the plasma site were observed. To reach 50%equilibrium the effect site requires 2.5±0.3min and the CSF 3.5±0.2min, to reach 95%the values were, respectively, 90± 27and 15± 1min. This suggests that CSF is kinetically distinguishable from the effect site.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. N. H. G. Holford and L. B. Sheiner. Pharmacokinetic and pharmacodynamic modeling in vivo.CRC Crit. Rev. Bioeng. 5:273–322 (1981).

    CAS  Google Scholar 

  2. D. R. Stanski, R. J. Hudson, T. D. Homer, L. J. Saidman, and E. Meathe. Pharmacodynamic modeling of thiopental anesthesia.J. Pharmacokin. Biopharm. 12:223–240 (1984).

    Article  CAS  Google Scholar 

  3. J. S. Scott, K. V. Ponganis, and D. R. Stanski. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanyl.Anesthesiology 62:234–241 (1985).

    Article  CAS  PubMed  Google Scholar 

  4. G. Segré. Kinetics of interaction between drugs and biological systems.Farmaco 23:907–918 (1968).

    Google Scholar 

  5. C. J. Hull, H. B. H. Van Beem, K. McLeod, A. Sibbald, and M. J. Watson. A pharmacodynamic model for pancuronium.Br. J. Anaesth. 50:1113–1123 (1978).

    Article  CAS  PubMed  Google Scholar 

  6. L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine.Clin. Pharmacol. Ther. 25:358–371 (1979).

    CAS  PubMed  Google Scholar 

  7. E. Fuseau and L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model.Clin. Pharmacol. Ther. 35:733–741 (1984).

    Article  CAS  PubMed  Google Scholar 

  8. J. D. Unadkat, F. Bartha, and L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.Clin. Pharmacol. Ther. 40:86–93 (1986).

    Article  CAS  PubMed  Google Scholar 

  9. D. Verotta, S. L. Beal, and L. B. Sheiner. Semiparametric approach to pharmacokineticpharmacodynamic data.Am. J. Physiol. 256:R1005-R1010 (1989).

    CAS  PubMed  Google Scholar 

  10. P. Veng-Pedersen, J. W. Mandema, and M. Danhof. A system approach to pharmacodynamics III: An algorithm and computer program ‘COLAPS’ for pharmacodynamic modeling.J. Pharm. Sci. 80:488–495 (1991).

    Article  CAS  PubMed  Google Scholar 

  11. J. W. Mandema and M. Danhof. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis.J. Pharmacokin. Biopharm. 18:459–481 (1990).

    Article  CAS  Google Scholar 

  12. J. B. M. M. van Bree, A. V. Baljet, A. van Geyt, A. G. de Boer, M. Danhof, and D. D. Breimer. The unit impulse response procedure for the pharmacokinetic evaluation of drug entry into the central nervous system.J. Pharmacokin. Biopharm. 17:441–462 (1989).

    Article  Google Scholar 

  13. P. Veng-Pedersen and W. R. Gillespie. A system approach to pharmacodynamics I: theoretical framework.J. Pharm. Sci. 77:39–47 (1988).

    Article  CAS  PubMed  Google Scholar 

  14. H. G. Boxenbaum, S. Riegelman, and R. M. Elashoff. Statistical estimations in pharmacokinetics.J. Pharmacokin. Biopharm. 2:123–148 (1974).

    Article  CAS  Google Scholar 

  15. M. Gibaldi and D. Perrier. Noncompartmental analysis based on statistical moment theory. InPharmacokinetics, 2nd ed. Marcel Dekker, New York, 1982, pp. 409–424.

    Google Scholar 

  16. P. Veng-Pedersen, J. W. Mandema, and M. Danhof. Biophase equilibration times.J. Pharm. Sci. 80:881–886 (1991).

    Article  CAS  PubMed  Google Scholar 

  17. W. F. Ebling, M. Danhof, and D. R. Stanski. Pharmacodynamic characterization of the electroencephalographic effects of thiopental in rats.J. Pharmacokin. Biopharm. 19:123–143 (1991).

    Article  CAS  Google Scholar 

  18. P. Veng-Pedersen. Linear and nonlinear systems approaches in pharmacokinetics: how much do they have to offer? II. The response mapping operator (RMO) approach.J. Pharmacokin. Biopharm. 16:543–571 (1988).

    Article  CAS  Google Scholar 

  19. P. O. Maitre, M. Bührer, S. L. Shafer, and D. R. Stanski. Estimating the rate of thiopental blood-brain equilibration using pseudo steady-state serum concentrations.J. Pharmacokin. Biopharm. 18:175–187 (1990).

    Article  CAS  Google Scholar 

  20. R. J. Hudson, D. R. Stanski, L. J. Saidman, and E. Meathe. A model for studying depth of aneshesia and acute tolerance to thiopental.Anesthesiology 59:301–308 (1983).

    Article  CAS  PubMed  Google Scholar 

  21. J. Dingemanse, D. Thomassen, B. H. Mentink, and M. Danhof. Strategy to assess the role of (inter)active metabolites in pharmacodynamic studies in vivo: a model study with heptabarbital.J. Pharm. Pharmacol. 40:552–557 (1988).

    Article  CAS  PubMed  Google Scholar 

  22. H. H. Frey and M. P. Magnussen. Contribution to the metabolism of amobarbital and the pharmacological significance of its main metabolite, 5-ethyl-5-(3-hydroxyisopentyl) barbituric acid.Arzneim. Forsch. (Drug Res.)16:612–615 (1966).

    CAS  Google Scholar 

  23. M. Danhof and G. Levy. Kinetics of drug action in disease states I. Effects of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex.J. Pharmacol. Exp. Ther. 229:44–50 (1984).

    CAS  PubMed  Google Scholar 

  24. S. Toon and M. Rowland. Structure-pharmacokinetic relationships among the barbiturates in the rat.J. Pharmacol. Exp. Ther. 225:752–763 (1983).

    CAS  PubMed  Google Scholar 

  25. M. Danhof, M. Hisaoka, and G. Levy. Kinetics of drug action in disease states. II. Effect of experimental renal dysfunction on phenobarbital concentrations in rats at onset of loss of righting reflex.J. Pharmacol. Exp. Ther. 230:627–631 (1984).

    CAS  PubMed  Google Scholar 

  26. J. Dingemanse, M. Polhuijs, and M. Danhof. Altered pharmacokinetic-pharmacodynamic relationship of heptabarbital in experimental renal failure in rats.J. Pharmacol. Exp. Ther. 241:371–376 (1988).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Supported by MEDIGON grant 900-521-106.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mandema, J.W., Veng-Pedersen, P. & Danhof, M. Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions. Journal of Pharmacokinetics and Biopharmaceutics 19, 617–634 (1991). https://doi.org/10.1007/BF01080870

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01080870

Key words

Navigation